In a previous study [1], we found that the tissue factor (TF) activity of microparticles (MP)
isolated from platelet-poor plasma (MP-TF activity) was markedly increased in patients with …

Cancer patients exhibit a high rate of thromboembolism (VTE). In this study, we analyzed
levels of microparticle (MP) tissue factor (TF) activity in cancer patients with or without VTE …

Background: Cancer, in particular mucinous adenocarcinoma, is associated with venous
thromboembolism (VTE). Tissue factor (TF), initiator of coagulation, plays a central role in the …

Background: Tissue factor (TF) expression by tumors contributes to tumor growth. Release of
TF‐positive microparticles (MPs) may contribute to venous thromboembolism (VTE) …

INTRODUCTION: Microparticles (MPs) carrying active tissue factor (TF) have been detected
in the plasma of cancer patients in particular in those presenting with acute deep vein …

Highly elevated microparticle (MP)-associated tissue factor (TF) activity was found in
patients with pancreatic cancer, one of the most prothrombotic malignancies. It remains to be …

Pancreatic cancer is the fourth leading cause of cancer death in the US [1]. It is frequently
complicated by venous thromboembolism (VTE), with published incidence rates varying …

Patients with cancer have an increased risk for venous thrombosis. Interestingly, different
cancer types have different rates of thrombosis, with pancreatic cancer having one of the …

BACKGROUND: Cancer patients have an increased risk of thrombosis. Tissue factor (TF)
antigen and TF activity associated with microparticles in plasma are elevated in patients with …

Tissue factor (TF) expressed on sub-cellular membrane vesicles, so-called plasma
microparticles (MPs), has recently emerged as a potential key player in intravascular …